• Home
  • News & IR
  • News
Digital Therapeutics
코로나19로 디지털치료제 수요 ↑…美 FDA, 올해만 6개 허가
2021-08-26
K-HUB
Hanmi Science consortium aims to be Asia-Pacific region’s vaccine hub
2021-08-25
Bio Vaccine
에스티팜, 테라젠바이오와 ‘mRNA 항암백신’ 연구개발 나선다
2021-08-18
Bio Vaccine
Hanmi Science has completed the development of six types of raw materials for mRNA vaccines
2021-08-17
K-HUB
한미약품, mRNA 코로나 백신 개발에 나서… “개발되면 모더나보다 경쟁력 있어”
2021-08-10
Bio Vaccine
MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200
2021-08-10
Bio Vaccine
테라젠바이오, '시그니처 유전자' 활용 맞춤형 항암제 선별 기술 특허
2021-08-09
Bio Vaccine
S.Korea pledges nearly $2 bln to become major COVID-19 vaccine producer
2021-08-05
Digital Therapeutics
진단•의료기기 분야 3354억 유입…디지털 치료제 '주목'
2021-08-05
  1.   
  2. 36
  3. 37
  4. 38
  5. 39
  6. 40
  7. 41
  8. 42
  9.   
  • 10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
  • Tel : 02-890-8700
  • IR Service : 02-6964-8770
  • Fax : 02-6964-8755

About Us

Goals & Promise

Leadership

Company History

IR

Notice & IR

Disclosure Information

Dx&Vx 2023 Award Impact

Contact

Private Policy Terms of Use twitter icon @dxvx_official
© 2024 Dx&Vx. All Rights Reserved.